ホーム / コンテンツ / オンデマンド・ウェビナー / Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
オンデマンド・ウェビナー

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases.

Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. Watch this video to learn what clinical pharmacology considerations oligonucleotide drug developers need to account for.

About Our Speaker

Dr. Virna Schuck is a Senior Director in Clinical Pharmacology and Translational Medicine at Certara. She has over 16 years of experience in Pharmaceutical Development, working across the Discovery and Development phases. Prior to joining Certara, Dr. Schuck held positions of increasing responsibility at Novartis, AstraZeneca, and Millennium Pharmaceuticals. Dr. Virna Schuck has a bachelor’s degree in pharmacy and master’s in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul – UFRGS- Brazil, and a PhD in Pharmaceutical Sciences from the College of Pharmacy, University of Florida.

トップに戻る
Powered by Translations.com GlobalLink OneLink Software